Clinical Trials Browser

Phase 2 × Active not recruiting × Transurethral Resection of Bladder × Clear all

NCT04164082 2026-03-18

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT04221503 2026-01-08

Niraparib/TTFields in GBM

Phase 2 Active not recruiting

Glioblastoma

NCT02792582 2025-11-12

A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

Phase 2 Active not recruiting

Brain Neoplasms, Craniopharyngioma

NCT02621151 2025-10-07

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

Phase 2 Active not recruiting

60 enrolled 11 charts

Muscle-invasive Urothelial Cancer of the Bladder

NCT02710734 2024-12-24

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Phase 2 Active not recruiting

Urothelial Carcinoma of the Bladder